WO2023094885 - ANTIGENIC DETERMINANTS, PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-COV-2
National phase entry is expected:
Publication Number
WO/2023/094885
Publication Date
01.06.2023
International Application No.
PCT/IB2022/000699
International Filing Date
23.11.2022
Title **
[English]
ANTIGENIC DETERMINANTS, PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-COV-2
[French]
DÉTERMINANTS ANTIGÉNIQUES, IMMUNITÉ PROTECTRICE, SÉRODIAGNOSTIC ET SOUS-UNITÉS MULTIVALENTES DE PRECISION VACCINE CONTRE SARS-COV-2
Applicants **
ARABIAN GULF UNIVERSITY
Salmaniya Medical Center
P.O. Box 26671
Manama, BH
Inventors
FATHALLAH, Mohamed-dahmani
C/o Arabian Gulf University
Salmaniya Medical Center
P.O. Box 26671
Manama, BH
TRABELSI, Khaled
C/o Arabian Gulf University
Salmaniya Medical Center
P.O. Box 26671
Manama, BH
KHALAF, Noureddine, Ben
C/o Arabian Gulf University
Salmaniya Medical Center
P.O. Box 26671
Manama, BH
RAMADAN, Ahmad, Rasmi
C/o Arabian Gulf University
Salmaniya Medical Center
P.O. Box 26671
Manama, BH
Priority Data
63/283,835
29.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2136 | |
| EPO | Filing, Examination | 7684 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3610 |
Total: 14596 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity.[French]
L'invention concerne des peptides immunogènes, des polypeptides, des sous-unités de protéine, des acides nucléiques les codant, des compositions et des vaccins contenant les peptides ou acides nucléiques immunogènes, ainsi que des méthodes de vaccination et/ou de traitement d'une infection par SARS-CoV-2. L'invention concerne également un dosage diagnostique sérologique ainsi qu'une utilisation du dosage sérologique avec le peptide P3 (SEQ ID NO : 3) afin de révéler si un être humain suspecté d'être infecté ou d'avoir été infecté par un virus du SARS-CoV-2 a généré une immunité protectrice contre le SARS-CoV-2.